Acuvue Theravision With Ketotifen is owned by Johnson Johnson Visn.
Acuvue Theravision With Ketotifen contains Ketotifen Fumarate.
Acuvue Theravision With Ketotifen has a total of 2 drug patents out of which 0 drug patents have expired.
Acuvue Theravision With Ketotifen was authorised for market use on 25 February, 2022.
Acuvue Theravision With Ketotifen is available in drug-eluting contact lens ;ophthalmic dosage forms.
The generics of Acuvue Theravision With Ketotifen are possible to be released after 27 June, 2030.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9474746||JOHNSON JOHNSON VISN||Methods for stabilizing oxidatively unstable compositions|| |
(5 years from now)
|US9962376||JOHNSON JOHNSON VISN||Methods and ophthalmic devices used in the treatment of ocular allergies|| |
(7 years from now)
|New Product (NP)||Feb 25, 2025|
Drugs and Companies using KETOTIFEN FUMARATE ingredient
Market Authorisation Date: 25 February, 2022
Dosage: DRUG-ELUTING CONTACT LENS ;OPHTHALMIC
Korea, Republic of
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic